CompletedNCT03446885

Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD

Medication studyAges 16–25United States

The study in practice

Understand this study

Listed age limits: 16 years to 25 years.

Listed locations: Buffalo, United StatesSee all locations and recruitment
Activities: Medication described in the protocol · Placebo described in the protocol; its role is not resolved here
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: April 1, 2018

Recruitment status: Completed
Enrollment listed in the registry: 22
Sponsor: Gregory Fabiano
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 4
Locations: United States
Age range: From 16 Years to 25 Years
Official registry ID: NCT03446885
Official title: Show the full official title
Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With Attention-deficit/Hyperactivity Disorder

Completed

Buffalo

FAQ

Who is behind this study?

The study sponsor is Gregory Fabiano.

Did this study involve medication?

Yes. The study involved medication, including Lisdexamfetamine Dimesylate 40 MG and Placebo.

Who was this study for?

Listed age limits: 16 years to 25 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.